London – September 27, 2018 – Cooley advised Orchard Therapeutics on its oversubscribed $150 million Series C financing. Partner Stephen Rosen led the Cooley team advising the company.
According to Orchard, the funding will be used to progress its three most advanced clinical programs towards registration and commercialization. The funding will also support the clinical and preclinical development of the company’s rare disease gene therapy pipeline.
Deerfield Management led the financing with significant new investments from RA Capital Management, Venrock, Foresite Capital, Perceptive Advisors, Cormorant Asset Management, ArrowMark Partners, Sphera Global Healthcare, Medison Ventures, Driehaus Capital Management and Ghost Tree Capital Group, as well as additional US-based healthcare funds.
“We are thrilled to have such strong support from both new and existing investors in this financing round,” said Mark Rothera, president and CEO of Orchard, in a news release. “The quality of this investor syndicate is a testament to the confidence we have built among our stakeholders, based on the substantial progress of Orchard’s clinical and preclinical programs since our Series B round last year.”
Orchard is a fully integrated commercial-stage biotechnology company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.